Last A$0.22 AUD
Change Today -0.015 / -6.52%
Volume 80.1K
As of 1:10 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PBT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/31/14 - A$1.37
52 Week Low
05/7/14 - A$0.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

prana biotechnology ltd (PBT) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd (PBT) Details

Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate includes PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds, which support new therapies for the treatment of neurodegenerative disease and other highly prevalent conditions. The company was founded in 1997 and is based in Parkville, Australia.

12 Employees
Last Reported Date: 09/30/14
Founded in 1997

prana biotechnology ltd (PBT) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$444.4K
Acting Chief Financial Officer
Total Annual Compensation: A$50.0K
Chief Operating Officer
Total Annual Compensation: A$324.8K
Company Secretary
Total Annual Compensation: A$80.0K
Compensation as of Fiscal Year 2014.

prana biotechnology ltd (PBT) Key Developments

Prana Biotechnology Limited Receives US Food and Drug Administration Orphan Drug Designation for PBT2 for Huntington Disease

Prana Biotechnology Limited has announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease. Orphan drug designation is granted by the FDA to promote the development of drugs for diseases affecting less than 200,000 people in the United States. Orphan drug designation entitles Prana to seven years of market exclusivity for the use of PBT2 in the treatment of Huntington disease; protocol assistance by the FDA to optimize drug development in the preparation of a dossier that will meet regulatory requirements; and reduced fees associated with applying for market approval. The company will also be applying for Orphan Drug designation in Europe and other jurisdictions. Prana announced in February 2014 that its lead MPAC (Metal Protein Attenuating Compound) PBT2 had met its primary end point of safety and tolerability, and improved measures of cognitive performance - a secondary endpoint in its Reach2HD Phase 2 clinical trial involving 109 people with Huntington disease. Prana is preparing its Post Phase 2 Trial dossier for submission to the FDA to commence discussions on the next development steps for PBT2.

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Year Ended June 30, 2014

Prana Biotechnology Limited reported consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue from ordinary activities of AUD 363,775 compared to AUD 150,867 a year ago, which is interest received on the group's bank accounts. The company has incurred a loss of AUD 13,329,239 compared to AUD 7,787,242 a year ago. This loss has increased due to an increase in R&D expenditure for the period offset by an increase in other income recognized under an Australian government tax incentive scheme introduced July 1, 2011. Loss before income tax expense was AUD 13,329,239 compared to AUD 7,787,242 a year ago. Diluted loss per share was 3.11 cents compared to 2.30 cents a year ago. Net operating cash out flows were AUD 13,788,974 compared to AUD 7,951,254 a year ago. Payment for purchases of plant and equipment was AUD 23,047 compared to AUD 22,000 a year ago. Net Tangible Assets per Share was 7.71 cents compared to 3.66 cents a year ago.

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Quarter Ended June 30, 2014

Prana Biotechnology Limited reported consolidated earnings results for the quarter ended June 30, 2014. Revenue was $93,135,000 compared to $131,863,000 a year ago. Loss from operating activities were $2,124,000 compared to income from operating activities was $2,270,000 a year ago. Loss before tax was $2,957,000 compared to profit before tax of $1,507,000 a year ago. Loss attributable to owners of the company was $4,432,000 compared to profit attributable to owners of the company of $607,000 a year ago. Net cash generated from operating activities was $5,932,000 compared to $14,923,000 a year ago. Purchase of property, plant and equipment amounted to $703,000 compared to $1,078,000 a year ago. Basic and diluted loss per share was 0.37 cents compared to basic and diluted EPS of 0.05 cents a year ago. The contraction in revenue was due to a slowdown in private construction activities, following the introduction of cooling measures to the private residential property sector. The effect of such measures was adversely felt by the construction sector in Singapore which has led to dampened construction demand.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBT:AU A$0.22 AUD -0.015

PBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBT.
View Industry Companies

Industry Analysis


Industry Average

Valuation PBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.8x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at